本帖最后由 老马 于 2012-1-13 21:20 编辑
% v# d( j: x- e Q+ ]
+ x- }1 d9 Y/ C t) Q爱必妥和阿瓦斯丁的比较
) D2 ]% Q3 m, S6 t, @1 y& p
! J, \; {5 G2 B* U% \# i" qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/) V6 F9 f+ B1 H$ @& t% V) u
6 G9 M8 U; t) U K
) l- L' _4 }" b8 |; g/ P
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# c/ a D3 m( J9 k5 f
==================================================9 p; p! ?' w0 H6 N
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 h* U0 V6 F* o1 M. z' Y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ O# q* v$ ]$ g- b1 C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 g& c8 P4 G; W' Y8 R R: B6 u
|